Endometrial stimulation by estrogen is postulated as the main driving force for endometrial polyp formation and this is supported by the observation that the use of tamoxifen, which acts as an ER agonist on the endometrium, increases the risk of developing endometrial polyps. The gene discussed is ESR1; the disease is endometrial polyp.